Reducing Costs Of Goods For Advanced Therapies

Cell and gene therapies are revolutionizing modern medicine — but high manufacturing costs remain a major barrier to global accessibility. In this insightful conversation, Gregg Nyberg, Ph.D., Chief Technology Officer at Landmark Bio, joins us to explore cutting-edge strategies for reducing the cost of goods (COGs) in both autologous and allogeneic cell therapies, as well as gene therapies utilizing viral and non-viral delivery systems.

With over 25 years of experience in biopharma manufacturing, Nyberg shares practical innovations — from automation and closed systems to novel vectors and nanoparticle delivery — that are shaping the future of scalable, affordable therapies. He also breaks down the technical and economic trade-offs between therapy types and offers a candid look at the hurdles that still need to be overcome.

Whether you're in biotech, healthcare, or just curious about the next frontier in medicine, this talk offers a rare window into the real-world challenges — and exciting opportunities — of making advanced therapies accessible for all.